Last reviewed · How we verify

NCT07027267: Gaia

Safety and Effectiveness of TurbAlign™ for Middle Turbinate Medialization After Functional Endoscopic Sinus Surgery

Active, enrolled NA Last updated 30 March 2026
What this trial tests

NA trial testing Implantation of Spirair device into the middle turbinates in Sinus Endoscopic Surgery in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
4 August 2025
Primary endpoint
5 May 2026
31 July 2026

Quick facts

Lead sponsorSpirair, Inc
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment50
Start date4 August 2025
Primary completion5 May 2026
Estimated completion31 July 2026
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Spirair, Inc — full company profile →

Who can join

Adults 18 to 70, any sex, with Sinus Endoscopic Surgery or Turbinate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study of a bioabsorbable implant to separate the middle turbinate from the lateral nasal wall associated with nasal/sinus surgery

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Spirair, Inc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07027267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing